| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Right-of-use asset | 0 | 34,918 | ||
| Prepaid research and development, noncurrent | 1,000,000 | - | ||
| Other assets | 57,913 | - | ||
| Total assets | 79,594,541 | 88,853,230 | ||
| Total stockholders' equity | 72,898,298 | 80,053,685 | ||
| Total liabilities and stockholders' equity | 79,594,541 | 88,853,230 | ||
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)